OncoCyte Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OncoCyte stock.
View analyst ratings for OncoCyte or view top-rated stocks.

Wall Street analysts have given OncoCyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OncoCyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

OncoCyte saw a drop in short interest during the month of January. As of January 29th, there was short interest totaling 1,990,000 shares, a drop of 21.3% from the January 14th total of 2,530,000 shares. Based on an average daily trading volume, of 2,200,000 shares, the short-interest ratio is currently 0.9 days.
View OncoCyte's Short Interest.

OncoCyte is scheduled to release its next quarterly earnings announcement on Tuesday, March 16th 2021.
View our earnings forecast for OncoCyte.

OncoCyte will be holding an earnings conference call on Tuesday, March 16th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

OncoCyte Co. (NYSEAMERICAN:OCX) released its quarterly earnings results on Thursday, November, 12th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. The biotechnology company had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.62 million.
View OncoCyte's earnings history.

OncoCyte's stock was trading at $2.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OCX stock has increased by 73.8% and is now trading at $3.72.
View which stocks have been most impacted by COVID-19.

7 equities research analysts have issued twelve-month price objectives for OncoCyte's stock. Their forecasts range from $4.00 to $7.75. On average, they expect OncoCyte's stock price to reach $5.11 in the next twelve months. This suggests a possible upside of 37.3% from the stock's current price.
View analysts' price targets for OncoCyte or view top-rated stocks among Wall Street analysts.

Some companies that are related to OncoCyte include Meridian Bioscience (VIVO), Aspira Women's Health (AWH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), VolitionRx (VNRX), Trinity Biotech (TRIB), ImmuCell (ICCC), Biomerica (BMRA), Navidea Biopharmaceuticals (NAVB), StageZero Life Sciences (GNWSF), StageZero Life Sciences (GNWSD), ARCA biopharma (ABIO), Achieve Life Sciences (ACHV) and Akers Biosciences (AKER).
View all of OCX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include Alibaba Group (BABA), BioTime (BTX), Fulcrum Therapeutics (FULC), Alnylam Pharmaceuticals (ALNY), VIVUS (VVUS), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), AcelRx Pharmaceuticals (ACRX), Agile Therapeutics (AGRX) and Aldeyra Therapeutics (ALDX).

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

OncoCyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pura Vida Investments LLC (9.34%), BlackRock Inc. (5.21%), Northern Trust Corp (1.01%), Penbrook Management LLC (0.63%), Nuveen Asset Management LLC (0.36%) and GSA Capital Partners LLP (0.25%). Company insiders that own OncoCyte stock include Albert P Parker, Alfred D Kingsley, Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews and Thomas Alex Vetter.
View institutional ownership trends for OncoCyte.

OCX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, and Barclays PLC.
View insider buying and selling activity for OncoCyte or view top insider-selling stocks.

OCX stock was acquired by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC, BlackRock Inc., Penbrook Management LLC, Nisa Investment Advisors LLC, Wells Fargo & Company MN, JPMorgan Chase & Co., Bank of New York Mellon Corp, and Virtu Financial LLC. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Andrew Arno, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews, and Thomas Alex Vetter.
View insider buying and selling activity for OncoCyte or or view top insider-buying stocks.

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OCX stock can currently be purchased for approximately $3.72.

OncoCyte has a market capitalization of $250.17 million. The biotechnology company earns $-22,430,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.

OncoCyte employs 33 workers across the globe.

The official website for OncoCyte is www.oncocyte.com.

OncoCyte is headquartered at 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States.

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515 or via email at [email protected]